GILD
Price
$118.48
Change
+$0.27 (+0.23%)
Updated
Oct 14 closing price
Capitalization
147.01B
8 days until earnings call
Intraday Buy/Sell Signals
NVS
Price
$130.26
Change
+$1.14 (+0.88%)
Updated
Oct 14 closing price
Capitalization
251B
13 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

GILD vs NVS

Header iconGILD vs NVS Comparison
Open Charts GILD vs NVSBanner chart's image
Gilead Sciences
Price$118.48
Change+$0.27 (+0.23%)
Volume$6.31M
Capitalization147.01B
Novartis AG
Price$130.26
Change+$1.14 (+0.88%)
Volume$1.56M
Capitalization251B
GILD vs NVS Comparison Chart in %
GILD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GILD vs. NVS commentary
Oct 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GILD is a Hold and NVS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 16, 2025
Stock price -- (GILD: $118.48 vs. NVS: $130.26)
Brand notoriety: GILD: Notable vs. NVS: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GILD: 93% vs. NVS: 116%
Market capitalization -- GILD: $147.01B vs. NVS: $251B
GILD [@Pharmaceuticals: Major] is valued at $147.01B. NVS’s [@Pharmaceuticals: Major] market capitalization is $251B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $728.24B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $96.1B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GILD’s FA Score shows that 4 FA rating(s) are green whileNVS’s FA Score has 3 green FA rating(s).

  • GILD’s FA Score: 4 green, 1 red.
  • NVS’s FA Score: 3 green, 2 red.
According to our system of comparison, NVS is a better buy in the long-term than GILD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GILD’s TA Score shows that 4 TA indicator(s) are bullish while NVS’s TA Score has 4 bullish TA indicator(s).

  • GILD’s TA Score: 4 bullish, 5 bearish.
  • NVS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both GILD and NVS are a good buy in the short-term.

Price Growth

GILD (@Pharmaceuticals: Major) experienced а +1.46% price change this week, while NVS (@Pharmaceuticals: Major) price change was -0.98% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.70%. For the same industry, the average monthly price growth was +0.81%, and the average quarterly price growth was +19.36%.

Reported Earning Dates

GILD is expected to report earnings on Oct 23, 2025.

NVS is expected to report earnings on Oct 28, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.70% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVS($251B) has a higher market cap than GILD($147B). GILD has higher P/E ratio than NVS: GILD (23.51) vs NVS (18.99). NVS YTD gains are higher at: 38.680 vs. GILD (30.988). GILD has less debt than NVS: GILD (24.9B) vs NVS (32.6B).
GILDNVSGILD / NVS
Capitalization147B251B59%
EBITDAN/A22.7B-
Gain YTD30.98838.68080%
P/E Ratio23.5118.99124%
RevenueN/A55.2B-
Total CashN/A7B-
Total Debt24.9B32.6B76%
FUNDAMENTALS RATINGS
GILD vs NVS: Fundamental Ratings
GILD
NVS
OUTLOOK RATING
1..100
1812
VALUATION
overvalued / fair valued / undervalued
1..100
16
Undervalued
16
Undervalued
PROFIT vs RISK RATING
1..100
1013
SMR RATING
1..100
2929
PRICE GROWTH RATING
1..100
3049
P/E GROWTH RATING
1..100
10047
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

GILD's Valuation (16) in the Biotechnology industry is in the same range as NVS (16) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to NVS’s over the last 12 months.

GILD's Profit vs Risk Rating (10) in the Biotechnology industry is in the same range as NVS (13) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to NVS’s over the last 12 months.

GILD's SMR Rating (29) in the Biotechnology industry is in the same range as NVS (29) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to NVS’s over the last 12 months.

GILD's Price Growth Rating (30) in the Biotechnology industry is in the same range as NVS (49) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to NVS’s over the last 12 months.

NVS's P/E Growth Rating (47) in the Pharmaceuticals Major industry is somewhat better than the same rating for GILD (100) in the Biotechnology industry. This means that NVS’s stock grew somewhat faster than GILD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GILDNVS
RSI
ODDS (%)
N/A
Bearish Trend 8 days ago
44%
Stochastic
ODDS (%)
Bearish Trend 8 days ago
45%
Bearish Trend 8 days ago
38%
Momentum
ODDS (%)
Bullish Trend 8 days ago
57%
Bullish Trend 8 days ago
45%
MACD
ODDS (%)
Bullish Trend 8 days ago
71%
Bullish Trend 8 days ago
55%
TrendWeek
ODDS (%)
Bullish Trend 8 days ago
58%
Bullish Trend 8 days ago
50%
TrendMonth
ODDS (%)
Bullish Trend 8 days ago
61%
Bullish Trend 8 days ago
46%
Advances
ODDS (%)
Bullish Trend 8 days ago
60%
Bullish Trend 15 days ago
50%
Declines
ODDS (%)
Bearish Trend 21 days ago
47%
Bearish Trend 9 days ago
44%
BollingerBands
ODDS (%)
Bearish Trend 8 days ago
46%
Bearish Trend 8 days ago
46%
Aroon
ODDS (%)
Bearish Trend 8 days ago
52%
Bullish Trend 8 days ago
46%
View a ticker or compare two or three
Interact to see
Advertisement
GILD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DIN27.931.64
+6.24%
Dine Brands Global
ADEA16.580.83
+5.27%
Adeia
UHAL55.920.20
+0.36%
U-Haul Holding Company
OSTX1.95N/A
N/A
OS Therapies Inc
FERAU10.50N/A
N/A
Fifth Era Acquisition Corp I

GILD and

Correlation & Price change

A.I.dvisor indicates that over the last year, GILD has been loosely correlated with BMY. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GILD jumps, then BMY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GILD
1D Price
Change %
GILD100%
+0.23%
BMY - GILD
46%
Loosely correlated
+0.60%
GSK - GILD
42%
Loosely correlated
+1.05%
AMGN - GILD
41%
Loosely correlated
+0.49%
NVS - GILD
40%
Loosely correlated
+0.88%
BIIB - GILD
39%
Loosely correlated
+0.43%
More

NVS and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVS has been closely correlated with GSK. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVS jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVS
1D Price
Change %
NVS100%
+0.88%
GSK - NVS
69%
Closely correlated
+1.05%
AZN - NVS
62%
Loosely correlated
+0.72%
PFE - NVS
60%
Loosely correlated
-0.85%
JNJ - NVS
55%
Loosely correlated
-0.03%
AMGN - NVS
54%
Loosely correlated
+0.49%
More